BMB-101

BMB-101 is a novel, highly selective, and potent small molecule agonist of the serotonin 5-HT2C receptor developed by Bright Minds Biosciences. It is specifically designed as a Gq-protein biased agonist, meaning it preferentially activates the Gq signaling pathway while avoiding beta-arrestin recruitment at the 5-HT2C receptor. This functional selectivity aims to minimize receptor desensitization and tolerance development, which are common issues in chronic neurological treatments. BMB-101 demonstrates over 100-fold selectivity for the 5-HT2C receptor compared to other serotonin receptors (such as 5-HT2A and 5-HT2B), reducing risks of psychedelic effects or cardiotoxicity seen with less selective agents like fenfluramine or lorcaserin. The drug is being developed primarily for refractory epilepsies—including absence epilepsy, Dravet syndrome, Lennox-Gastaut syndrome—and Pitt-Hopkins syndrome; it is also under investigation for binge-eating disorder and opioid-related disorders. Preclinical studies show anticonvulsant efficacy via inhibition of CaV3 calcium channels through activation of the target receptor[2][3][5][6][8][9].